Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of KalVista Pharmaceuticals, Inc. from 30 Apr 2018 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Apr 2018 to 31 Jul 2025.
  • KalVista Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Jul 2025 was $7,308,000, a 12486% decline year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $100,483,000.
  • KalVista Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $24,449,000, a 196% decline from 2022.
  • KalVista Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $25,506,000.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $7,308,000 -$7,367,000 -12486% 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q2 2024 $59,000 +$6,888,000 01 May 2024 31 Jul 2024 10-Q 11 Sep 2025 2026 Q1
Q2 2023 $6,829,000 -$13,960,000 -196% 01 May 2023 31 Jul 2023 10-Q 05 Sep 2024 2025 Q1
Q2 2022 $7,131,000 +$9,380,000 01 May 2022 31 Jul 2022 10-Q 07 Sep 2023 2024 Q1
Q2 2021 $2,249,000 -$4,474,000 -201% 01 May 2021 31 Jul 2021 10-Q 08 Sep 2022 2023 Q1
Q2 2020 $2,225,000 +$4,124,000 01 May 2020 31 Jul 2020 10-Q 09 Sep 2021 2022 Q1
Q2 2019 $1,899,000 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2021 Q1

KalVista Pharmaceuticals, Inc. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $100,483,000 +$124,932,000 01 May 2024 30 Apr 2025 10-K 10 Jul 2025 2025 FY
2023 $24,449,000 -$49,955,000 -196% 01 May 2023 30 Apr 2024 10-K 10 Jul 2025 2025 FY
2022 $25,506,000 +$45,366,000 01 May 2022 30 Apr 2023 10-K 11 Jul 2024 2024 FY
2021 $19,860,000 -$54,663,000 -157% 01 May 2021 30 Apr 2022 10-K 11 Jul 2024 2024 FY
2020 $34,803,000 +$51,020,000 01 May 2020 30 Apr 2021 10-K 10 Jul 2023 2023 FY
2019 $16,217,000 +$2,832,000 +15% 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
2018 $19,049,000 -$39,154,000 -195% 01 May 2018 30 Apr 2019 10-K 13 Jul 2021 2021 FY
2017 $20,105,000 01 May 2017 30 Apr 2018 10-K 01 Jul 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.